HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 [Yahoo! Finance]
HUTCHMED (China) Limited - American Depositary Shares (HCM)
NASDAQ:AMEX Investor Relations:
chi-med.com/investors/information-for-shareholders
Company Research
Source: Yahoo! Finance
announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois. Details of the presentations are as follows: Abstract title Presenter / Lead author Presentation details SPONSORED STUDIES Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors Xianwen Yang, HUTCHMED, Shanghai, China Poster Session (PO.ET03.04) Tuesday, April 29, 2025 SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi Jonathan W. Riess, University of California, UC Davis Comprehensive Cancer Center, CA, US LB416 Late-Breaking Poster Session (LBPO.CL04) Wednesday, April 30, 2025 A phase I open-label p
Show less
Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCM alerts
High impacting HUTCHMED (China) Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
HCM
News
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]Yahoo! Finance
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic CholangiocarcinomaGlobeNewswire
- HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid TumorsGlobeNewswire
- HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in ChinaGlobeNewswire
- HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual MeetingGlobeNewswire
HCM
Sec Filings
- 12/29/25 - Form 6-K
- 12/17/25 - Form 6-K
- 12/8/25 - Form 6-K
- HCM's page on the SEC website